Navigation Links
West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
Date:9/4/2012

LIONVILLE, Pa., Sept. 4, 2012 /PRNewswire/ -- West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by Janssen Biotech, has been specifically designed to meet the needs of patients by facilitating easier self-injection of pharmaceutical and biologic drug products. West will market the new injection technology under the name SelfDose™ (http://www.selfdose.com/).

(Logo: http://photos.prnewswire.com/prnh/20120904/NE65950LOGO )

West will be responsible for co-developing and handling the commercial scale-up and manufacture of the product, and will have the ability to offer the SelfDose injection technology as part of its expanding portfolio of self-injection technology platforms. The SelfDose injection technology complements West's ConfiDose® and SmartDose® injection technologies, and offers a solution for improved manual injection.

Providing the best solution to the challenges of packaging and delivering today's sensitive and complex biopharmaceutical products requires not only an effective drug container, but also a delivery system that can enable safe, effective and reliable delivery of the medication, especially when the administrator may be a patient. The SelfDose injection technology can help meet these challenges.

"We are delighted to have formalized our relationship with Janssen Biotech around this drug delivery platform and look forward to working together to commercialize the SelfDose injection technology, providing manufacturing, development and regulatory support through the remainder of the process," said Donald E. Morel, Jr., Ph.D., West's Chairman and CEO. "We value the opportunity to strengthen our long-standing relationship and are excited by this agreement. We look forward to working with Janssen to help them meet their business goals to restore health and serve patients."

About West

West's innovative system, device and component solutions help improve the safety and administration of injectable drugs. West's proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2011 totaled US$1.2 billion. West supports its customers from sales, manufacturing, customer support and research and development from locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at http://www.westpharma.com. Follow West on Twitter: http://www.twitter.com/WestPharma

SelfDose™ is a trademark of West.

ConfiDose® is a registered trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.

SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.

Media Contact:
Kristin Villiotte
Schwartz MSL
(781) 684-0770
westpharma@schwartzmsl.com

Investor Contact:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
Michael.Anderson@westpharma.com

 


'/>"/>
SOURCE West
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. TeleTracking Announces Real-Time Locating System (RTLS) Contract with Geisinger Health
3. VirtualScopics Announces Receipt of Notice from Nasdaq
4. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
5. Sihuan Pharmaceutical Announces 2012 Interim Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
8. SkinMedica Announces Collaboration Agreement with Massachusetts General Hospital for Research and Development of Pigmentation Products
9. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
10. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
11. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):